• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

原发灶不明癌与BRAF V600E符合BEACON联合治疗方案：一例病例报告

Cancer of unknown primary and BRAF V600E meeting the BEACON combination: A case report.

作者信息

Maly Marlies, Vanwalleghem Lieve, Van Den Eeckhaut Anja, De Wilde Vincent

机构信息

Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.

Department of Gastroenterology and Hepatology, AZ Sint-Jan, 8000 Bruges, Belgium.

出版信息

Mol Clin Oncol. 2024 Sep 30;21(6):88. doi: 10.3892/mco.2024.2786. eCollection 2024 Dec.

DOI:10.3892/mco.2024.2786
PMID:39391046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11462391/
Abstract

The diagnostic work-up of cancer of unknown primary (CUP) is a challenging task; in addition, only a little data on BRAF targeting in CUP are currently available. Traditionally, the identification of favourable and unfavourable CUP subsets directs the choice of treatment. The present article reports the case of a 50-year-old male patient presenting with a BRAF-mutated CUP, a rare and generally unfavourable subset. Based on imaging, immunohistochemistry and a high value of carbohydrate antigen 19-9, an upper gastrointestinal profile was initially presumed. After disease progression on treatment with a first-line platinum-based doublet chemotherapy, a significant response was documented after treatment with the BEACON combination. The present case report highlighted the paradigm shift in diagnosis and treatment of CUP from a histology-based approach to molecular profiling with the introduction of precision medicine.

摘要

未知原发灶癌症（CUP）的诊断性检查是一项具有挑战性的任务；此外，目前关于CUP中BRAF靶向治疗的可用数据很少。传统上，识别有利和不利的CUP亚组指导治疗选择。本文报告了一例50岁男性患者，其患有BRAF突变的CUP，这是一种罕见且通常预后不良的亚组。基于影像学、免疫组织化学和高碳水化合物抗原19-9值，最初推测为上消化道病变。在一线铂类双联化疗治疗后疾病进展，使用BEACON组合治疗后记录到显著反应。本病例报告强调了随着精准医学的引入，CUP的诊断和治疗从基于组织学的方法向分子谱分析的范式转变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/71e0b77130e3/mco-21-06-02786-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/c72f4c27047b/mco-21-06-02786-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/8d4dec582496/mco-21-06-02786-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/43a51f8cb79a/mco-21-06-02786-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/5f97690cad5f/mco-21-06-02786-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/71e0b77130e3/mco-21-06-02786-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/c72f4c27047b/mco-21-06-02786-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/8d4dec582496/mco-21-06-02786-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/43a51f8cb79a/mco-21-06-02786-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/5f97690cad5f/mco-21-06-02786-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/71e0b77130e3/mco-21-06-02786-g04.jpg

相似文献

1
Cancer of unknown primary and BRAF V600E meeting the BEACON combination: A case report.原发灶不明癌与BRAF V600E符合BEACON联合治疗方案：一例病例报告
Mol Clin Oncol. 2024 Sep 30;21(6):88. doi: 10.3892/mco.2024.2786. eCollection 2024 Dec.
2
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With V600E Mutation: A Case Report.阿替利珠单抗联合铂类化疗对未经治疗的非吸烟V600E突变肺腺癌患者的持久反应：一例报告
Front Oncol. 2021 Jun 10;11:634920. doi: 10.3389/fonc.2021.634920. eCollection 2021.
3
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.携带BRAF突变的肿瘤类型无关疗法：病例报告及文献综述
Pharmaceuticals (Basel). 2021 Feb 16;14(2):159. doi: 10.3390/ph14020159.
4
Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.达拉非尼联合曲美替尼治疗携带 BRAF 突变的胆道癌患者（ROAR）：一项 2 期、开放标签、单臂、多中心篮子试验。
Lancet Oncol. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17.
5
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.恩考芬尼、比尼替尼和西妥昔单抗联合用于治疗 BRAF 突变型转移性结直肠癌的安全性和疗效：日本扩大准入计划的结果。
Clin Colorectal Cancer. 2024 Jun;23(2):174-182.e6. doi: 10.1016/j.clcc.2024.02.002. Epub 2024 Mar 9.
6
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.一项每日恩考芬尼联合每两周西妥昔单抗治疗 BRAF V600E 突变转移性结直肠癌患者的 II 期研究：NEW BEACON 研究。
BMC Cancer. 2022 Dec 16;22(1):1321. doi: 10.1186/s12885-022-10420-x.
7
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary.不明原发癌诊断与治疗中的新基因技术
Cancers (Basel). 2022 Jul 14;14(14):3429. doi: 10.3390/cancers14143429.
8
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.分子指导的治疗与疾病控制后的化疗在不利的癌症未知原发性（CUPISCO）：一个开放标签，随机，2 期研究。
Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31.
9
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.一项具有挑战性的任务：根据 ESMO 指南识别癌症未知原发灶（CUP）患者：CUPISCO 试验经验。
Oncologist. 2021 May;26(5):e769-e779. doi: 10.1002/onco.13744. Epub 2021 Mar 25.
10
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.encorafenib/西妥昔单抗联合或不联合 binimetinib 治疗 BRAF V600E 突变型转移性结直肠癌患者的疗效和安全性：一项 ACEO 真实世界多中心研究。
ESMO Open. 2024 Sep;9(9):103696. doi: 10.1016/j.esmoop.2024.103696. Epub 2024 Sep 9.

本文引用的文献

1
Rare axillary cancer of unknown primary originating from the breast of a 64‑year‑old male patient: A case report and literature review.一名64岁男性患者源自乳腺的罕见原发性不明的腋窝癌：病例报告及文献综述
Oncol Lett. 2024 Jan 5;27(2):86. doi: 10.3892/ol.2024.14220. eCollection 2024 Feb.
2
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.原发灶不明癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Mar;34(3):228-246. doi: 10.1016/j.annonc.2022.11.013. Epub 2022 Dec 20.
3
The Evolving Treatment Landscape in -Mutated Metastatic Colorectal Cancer.
- 突变型转移性结直肠癌的治疗现状进展
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-10. doi: 10.1200/EDBK_349561.
4
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study.肿瘤标志物在识别不明原发癌患者中有利或不利亚组的诊断价值：一项回顾性研究。
BMC Cancer. 2022 Apr 14;22(1):412. doi: 10.1186/s12885-022-09514-3.
5
Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX.原发灶不明且疑似胰腺癌的癌症采用FOLFIRINOX方案治疗。
J Med Cases. 2021 Nov;12(11):442-445. doi: 10.14740/jmc3812. Epub 2021 Nov 5.
6
Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).不明原发癌（CUP）中的基因组改变和可能的可用药突变。
Sci Rep. 2021 Jul 23;11(1):15112. doi: 10.1038/s41598-021-94678-4.
7
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.携带BRAF突变的肿瘤类型无关疗法：病例报告及文献综述
Pharmaceuticals (Basel). 2021 Feb 16;14(2):159. doi: 10.3390/ph14020159.
8
Cancer of Unknown Primary in the Molecular Era.分子时代的不明原发癌
Trends Cancer. 2021 May;7(5):465-477. doi: 10.1016/j.trecan.2020.11.002. Epub 2021 Jan 28.
9
Cancer of Unknown Primary: Challenges and Progress in Clinical Management.原发灶不明癌：临床管理中的挑战与进展
Cancers (Basel). 2021 Jan 25;13(3):451. doi: 10.3390/cancers13030451.
10
Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.糖类抗原19-9——肿瘤标志物：过去、现在与未来
World J Gastrointest Surg. 2020 Dec 27;12(12):468-490. doi: 10.4240/wjgs.v12.i12.468.